PUBLICATION: 
Breast Cancer Res Treat (2016) 159: 481. https://doi.org/10.1007/s10549-016-3949-y09.
AUTHORS:
Raquel A. Nunes, Lynette Wray, Mihriye Mete, Pia Herbolsheimer, Karen L. Smith, Lana Bijelic, Marc E. Boisvert, Sandra M. Swain
SUMMARY:
We evaluated gene expression in tumors from AAF presenting with early stage or locally advanced breast cancer using MammaPrint, BluePrint (molecular subtype) and TargetPrint, correlated with OncotypeDX and clin-path. High Risk MammaPrint was present in 66% of patients and in 52% of patients with stage I disease.
